We are happy to announce that DeepPath as part of a consortium consisting of MIDA Biotech B.V. (an Orgenesis Inc. company), Leiden University, and MIRCOD LLC, acquired a €4m Pathfinder grant from European Innovation Council and SMEs Executive Agency (EISMEA) for the development of an Ai-powered platform to democratize autologous IPCS manufacturing! This is a great opportunity to utilize our know-how in AI to bring cutting-edge personalized celltherapy to hospitals all around the globe!
